Stock Analyst Note
Ipsen Earnings: New Licensing Agreement, Pipeline, and Growth Drugs Should Counter Generic Erosion
Narrow-Moat Ipsen reported solid half-yearly results highlighted by total sales of $1.66 billion, representing 8% growth from the prior-year period. Strong sales from high-growth drugs (Dysport, Cabometyx, and Onivyde) continued to drive revenue, and these drugs helped offset declining sales of Ipsen's leading oncology product, Somatuline, which has experienced competition and adverse pricing from generics.